Predicting diarrhea risk from liver cancer treatment using traditional Chinese medicine
Part of Cancer, Digestive system clinical trials.
This study looks at whether your body type according to traditional Chinese medicine (TCM) can predict diarrhea caused by combining immunotherapy and targeted therapy for liver cancer. The goal is to help doctors better manage and prevent this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer).
- You are planning to receive combined immunotherapy and anti-angiogenic targeted therapy (treatment that blocks blood vessels that feed the tumor).
- You are at least 18 years old and can complete questionnaires independently.
- You have normal hearing, speaking, reading, and writing abilities, and you agree to participate by signing a consent form.
- You do not have chronic diarrhea, inflammatory bowel disease, or cancer that has spread to the bowel.
- You have not been using laxatives for a long time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the bacteria in your gut (microbiome) affect liver cancer treatment. It aims to learn if certain gut bacteria can predict how well the combination of targeted therapy and immunotherapy works.
This study looks at how the bacteria in your gut (microbiome) might affect treatment for liver cancer. It tests a combination of targeted therapy and immunotherapy, which are already approved for liver cancer. The goal is to see if gut bacteria can predict how well the treatment works.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
This study is creating a database of people with liver cancer (including hepatocellular carcinoma and other types). It aims to collect health information and samples over time to better understand the disease and improve future care. If you join, you will be asked to provide blood and leftover tissue from surgery or biopsy, and to follow up with the research team.
This study looks at a genetic test that may predict how well liver cancer patients respond to combination treatment with targeted therapy and immunotherapy. If eligible, your stored tumor tissue will be analyzed to see if a specific gene pattern can tell whether this treatment works for you.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.